scholarly journals HspA1B Is a Prognostic Biomarker and Correlated With Immune Infiltrates in different subtypes of Breast Cancers

2019 ◽  
Author(s):  
Jian He ◽  
Hui Wang

ABSTRACTBackgroundHeat shock A1B, also known as HSP70kDa protein 1B, encodes a 70kDa heat shock protein which is a member of the heat shock protein 70 family. HspA1B is a critical gene which related to many type of diseases by involving in the ubiquitin-proteasome pathway. However, the correlations of HspA1B to prognosis and tumor-infiltrating lymphocytes in different cancers remain unclear.MethodsHspA1B expression was evaluated on the Oncomine database and Tumor Immune Estimation Resource (TIMER) site. We analyzed the influence of HspA1B on clinical prognosis using Kaplan-Meier plotter, the PrognoScan database and Gene Expression Profiling Interactive Analysis (GEPIA). The correlations between HspA1B and cancer immune infiltrates was investigated via TIMER. In addition, correlations between HspA1B expression and gene marker sets of immune infiltrates were analyzed by TIMER and GEPIA.ResultsThree cohorts (GSE9195, GSE9893, GSE3494-GPL96)) of breast cancer patients showed that high HspA1B expression was associated with poorer overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS). In addition, high HspA1B expression was significantly correlated with poor OS and progression-free survival (PFS) in bladder cancer, brain cancer and skin cancer. Moreover, HspA1B significantly impacts the prognosis of diverse cancers via The Cancer Genome Atlas (TCGA). HspA1B expression was positively correlated with infiltrating levels of CD4+ T and CD8+ T cells, macrophages, neutrophils, and dendritic cells (DCs) indifferent subtypes of Breast cancer. HspA1B expression showed strong correlations with diverse immune marker sets in BRCA-Luminal.ConclusionsOur findings suggest that HspA1B is correlated with prognosis and immune infiltrating levels of, including those of CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and DCs in multiple cancers, especially in colon and gastric cancer patients. In addition, HspA1B expression potentially contributes to regulation of tumor-associated macrophages (TAMs), DCs, T cell exhaustion and Tregs in colon and gastric cancer. These findings suggest that HspA1B can be used as a prognostic biomarker for determining prognosis and immune infiltration in BRCA-Luminal subtype.

2020 ◽  
Vol 7 ◽  
Author(s):  
Aizhai Xiang ◽  
Xia Lin ◽  
Lvping Xu ◽  
Honggang Chen ◽  
Jufeng Guo ◽  
...  

BackgroundThe exact biological role of PCOLCE was not yet clear and there were few reports study the correlation of PCOLCE gene expression level with the occurrence and development of gastric cancer.MethodsThe expression of PCOLCE was analyzed by performing the Oncomine and Ualcan database. We evaluated the function of PCOLCE on clinical prognosis with the use of Kaplan–Meier plotter database. The relationship between PCOLCE and cancer immune in filtrates was researched by Tumor Immune Estimation Resource (TIMER) site database.ResultsPCOLCE significantly upregulated in gastric cancer patients compared to normal gastric samples. And the increased expression of PCOLCE mRNA was closely linked to shorter overall survival (OS), progress-free survival (PFS) in all gastric cancers. Besides, PCOLCE expression displayed a tight correlation with infiltrating levels of macrophages and dendritic cells (DCs) in gastric cancer. Moreover, PCOLCE expression was positively correlated with diverse immune marker sets in gastric cancer.ConclusionAll the results above suggested that overexpression of PCOLCE indicated unfavorable prognosis in patients with gastric cancer. PCOLCE was correlated with immune infiltrating levels including those of B cells, CD8 + T cells, CD4 + T cells, macrophages, neutrophils, and DCs in gastric cancer patients. All the findings suggested that PCOLCE could be used as a prognostic biomarker for determining prognosis and immune infiltration in gastric cancer. Additionally, PCOLCE expression potentially contributed to the regulation of monocyte, M2 macrophage, Tfh, CD8 + T cell, TAM, Th1 cell Thus PCOLCE is a potential target for gastric cancer therapy and these preliminary findings require further study to determine whether PCOLCE-targeting reagents might be developed for clinical application in gastric cancer.


2021 ◽  
Author(s):  
Yanling Ma ◽  
WenBo Qi ◽  
BaoHong Gu ◽  
XueMei Li ◽  
ZhenYu Yin ◽  
...  

Abstract Objective: To investigate the association between ILDR1 and prognosis and immune infiltration in gastric cancer. Methods: We analyzed the RNA sequencing data of 9736 tumor tissues and 8587 normal tissues in the TCGA and GTEx databases through the GEPIA2 platform. The expression of ILDR1 in gastric cancer and normal gastric mucosa tissues with GEPIA and TIMER. Clinical subgroup analysis was made through Kaplan-Meier analysis. Analyzed the correlation between ILDR1 and VEGFA expression in gastric cancer, through the gene sequencing data of gastric cancer in TCGA. Explored the relationship between ILDR1 methylation and the prognosis of gastric cancer patients through the MethSurv database. The correlation between ILDR1 and immune cells and the correlation of copy number variation were explored through the TIMER database. Results: ILDR1-high GC patients had a lower PFS and OS. High ILDR1 expression was significantly correlated with tumor grade. There was a negative correlation between the ILDR1 expression and the abundances of CD8+ T, Macrophages and DC and etc. The methylation level of ILDR1 is associated with a good prognosis of gastric cancer. ILDR1 copy number variation was correlated with immune cells, IDLR1 arm-loss was associated with the infiltration of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells, and arm-duplication was associated with the infiltration of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils and dendritic cells. Conclusion: The increased expression of ILDR1 is associated with poor prognosis in patients with gastric cancer. ILDR1 can be used as a novel predictive biomarker to provide a new therapeutic target for gastric cancer patients.


2005 ◽  
Vol 35 (4) ◽  
pp. 1046-1055 ◽  
Author(s):  
Florian Winau ◽  
Anne-Marit Sponaas ◽  
Stephan Weber ◽  
Vera Schwierzeck ◽  
Ralf Winter ◽  
...  

2021 ◽  
Vol 10 (1) ◽  
pp. 1915560
Author(s):  
Kaifeng Jin ◽  
Yifan Cao ◽  
Yun Gu ◽  
Hanji Fang ◽  
Yuchao Fei ◽  
...  

2002 ◽  
Vol 169 (10) ◽  
pp. 5622-5629 ◽  
Author(s):  
Lisa A. E. Harmala ◽  
Elizabeth G. Ingulli ◽  
Julie M. Curtsinger ◽  
Michelle M. Lucido ◽  
Clint S. Schmidt ◽  
...  

JCI Insight ◽  
2019 ◽  
Vol 4 (19) ◽  
Author(s):  
Colt A. Egelston ◽  
Christian Avalos ◽  
Travis Y. Tu ◽  
Anthony Rosario ◽  
Roger Wang ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Ashley J. Schlafstein ◽  
Allison E. Withers ◽  
Soumon Rudra ◽  
Diana Danelia ◽  
Jeffrey M. Switchenko ◽  
...  

Failure to achieve pathologic complete response is associated with poor prognosis in breast cancer patients following neoadjuvant chemotherapy (NACT). However, prognostic biomarkers for clinical outcome are unclear in this patient population. Cyclin-dependent kinase 9 (CDK9) is often dysregulated in breast cancer, and its deficiency results in genomic instability. We reviewed the records of 84 breast cancer patients from Emory University’s Winship Cancer Institute who had undergone surgical resection after NACT and had tissue available for tissue microarray analysis (TMA). Data recorded included disease presentation, treatment, pathologic response, overall survival (OS), locoregional recurrence free survival (LRRFS), distant-failure free survival (DFFS), recurrence-free survival (RFS), and event-free survival (EFS). Immunohistochemistry was performed on patient samples to determine CDK9 expression levels after NACT. Protein expression was linked with clinical data to determine significance. In a Cox proportional hazards model, using a time-dependent covariate to evaluate the risk of death between groups beyond 3 years, high CDK9 expression was significantly associated with an increase in OS (HR: 0.26, 95% CI: 0.07-0.98, p=0.046). However, Kaplan-Meier curves for OS, LRRFS, DFFS, RFS, and EFS did not reach statistical significance. The results of this study indicate that CDK9 may have a potential role as a prognostic biomarker in patients with breast cancer following NACT. However, further validation studies with increased sample sizes are needed to help elucidate the prognostic role for CDK9 in the management of these patients.


2019 ◽  
Vol 12 (3) ◽  
pp. 585-595 ◽  
Author(s):  
Ivana Catacchio ◽  
Nicola Silvestris ◽  
Emanuela Scarpi ◽  
Laura Schirosi ◽  
Anna Scattone ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document